case_images: PMC6301300_01
case_images: Chest X-ray and CT scan before treatment with ceritinib.
case_images: ott-12-015Fig1.jpg
case_images: PMC6301300_01_ott-12-015Fig1.jpg
case_images: f1-ott-12-015
case_images: Prior to the third line of chemotherapy, the patient was weakened with the ECOG-PS 3 because of anorexia, dyspnea, dysphagia, and cachexia (Figure 1).
case_images: CT scan before introducing ceritinib (A, C), and 6 weeks after treating with ceritinib (B, D). Reduction of the primary tumor and plural effusion was revealed after the treatment.
case_images: ott-12-015Fig2.jpg
case_images: PMC6301300_01_ott-12-015Fig2.jpg
case_images: f2-ott-12-015
case_images: Abdominal metastatic lymph node also decreased in size and was assessed as showing partial response according to the Response Evaluation Criteria in Solid Tumors (RECIST version 1.1) for at least 2 months (Figure 2A-D).